Clinical Trials | October 23, 2025
Pimicotinib delivers lasting tumor responses and sustained symptom relief in TGCT patients
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Adding one year of Imfinzi treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and sustained disease-free survival benefit vs. BCG alone
Expanding US operations to address the increased demand for API development and manufacturing
The initial $100 million will fund a state-of-the-art hard-shell capsule facility in Atlanta
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Triamcinolone Acetonide injectable suspension USP is indicated for various autoimmune, inflammatory, and other conditions
Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
This partnership marks a significant step in strengthening Healthium’s position in the cardiac care segment
Sourced and formulated in the United States, Ameriflor Calm is derived from plants grown on regenerative organic certified farms and is manufactured at a site that uses 100% renewable electricity
Subscribe To Our Newsletter & Stay Updated
